Catalent Inc (CTLT +$2.74 or +2.22% to $126.40) recently violated prior lows in the $126-127 area and its 50-day moving average (DMA) line triggering technical sell signals. Its Relative Strength Rating has slumped to 63, below the 80+ minimum guideline for buy candidates. A rebound above the 50 DMA line is needed for its outlook to improve.

Fundamentals remain strong after it reported Sep '21 quarterly earnings +65% on +21% sales revenues versus the year ago period, its 6th quarterly comparison above the +25% minimum earnings guideline (C criteria). Annual earnings (A criteria) history has been steadily improving after a downturn in FY '16. It has a 93 Earnings Per Share Rating.

CTLT finished strong after highlighted in yellow with pivot point cited based on its 2/16/21 high plus 10 cents in the 8/25/21 mid-day report (read here). It was last shown in this FSU section on 10/08/21 with an annotated graph under the headline, "Found Support Near Prior High While Consolidating".

The company hails from the Medical - Research Equipment/Services group which is currently ranked 78th on the 197 Industry Groups list (L criteria). The number of top-rated funds owning its shares rose from 1,121 in Sep '20 to 1,472 in Sep '21, a reassuring sign concerning the I criteria. The current Up/Down Volume Ratio of 0.9 is an unbiased indication its shares have ben under accumulatio over the past 50 days. It has a Timeliness Rating of C and Sponsorship Rating of B.

There are 171.2 million shares outstanding (S criteria). CTLT completed new Public Offerings in Jun '20, Feb '20, Jul '18, and Sep '17. Completed Secondary Offerings in Jun and Sep '16, and Mar and Jun '15. Completed its $21 IPO on 7/31/14.

Catalent Inc (CTLT -$0.70 or -0.53% to $130.34) has been consolidating after volume-driven losses, trading near its 50-day moving average (DMA) line ($130.19) and above prior highs in the $124-127 area which define important near-term support to watch.

CTLT finished strong after highlighted in yellow with pivot point cited based on its 2/16/21 high plus 10 cents in the 8/25/21 mid-day report (read here). Volume was +69% above average behind today's 5th consecutive gain while hitting a new all-time high (N criteria). The gain and close above its pivot point clinched a technical buy signal. It was shown in greater detail that evening with an annotated graph under the headline, "Strong Gain Triggered Technical Buy Signal".

Fundamentals remain strong. The company reported its Jun '21 quarterly earnings rose +29% on +25% sales revenues versus the year ago period, its 5th quarterly comparison above the +25% minimum earnings guideline (C criteria). Annual earnings (A criteria) history has been steadily improving after a downturn in FY '16. It has a 90 Earnings Per Share Rating.

The company hails from the Medical - Research Equipment/Services group which is currently ranked 22nd on the 197 Industry Groups list (L criteria). The number of top-rated funds owning its shares rose from 1,121 in Sep '20 to 1,455 in Jun '21, a reassuring sign concerning the I criteria. The current Up/Down Volume Ratio of 1.4 is an unbiased indication its shares have ben under accumulatio over the past 50 days. It has a Timeliness Rating of B and Sponsorship Rating of B.

There are 171 million shares outstanding (S criteria). CTLT completed new Public Offerings in Jun '20, Feb '20, Jul '18, and Sep '17. Completed Secondary Offerings in Jun and Sep '16, and Mar and Jun '15. Completed its $21 IPO on 7/31/14.

Catalent Inc (CTLT +$2.90 or +2.30% to $129.15) finished strong after highlighted in yellow with pivot point cited based on its 2/16/21 high plus 10 cents in the earlier mid-day report (read here). Volume was +69% above average behind today's 5th consecutive gain while hitting a new all-time high (N criteria). The gain and close above its pivot point clinched a technical buy signal.

The company is scheduled to report its Jun '21 quarterly results on 8/30/21. Volume and volatility often increase near earnings news. Earnings rose +64% on +38% sales revenues for the Mar '21 quarter versus the year ago period, its 4th quarterly comparison above the +25% minimum earnings guideline (C criteria). Annual earnings (A criteria) history has been steadily improving after a downturn in FY '16. It has a 91 Earnings Per Share Rating.

The company hails from the Medical - Research Equipment/Services group which is currently ranked 32nd on the 197 Industry Groups list (L criteria). The number of top-rated funds owning its shares rose from 1,121 in Sep '20 to 1,434 in Jun '21, a reassuring sign concerning the I criteria. The current Up/Down Volume Ratio of 1.4 is an unbiased indication its shares have ben under accumulatio over the past 50 days. It has a Timeliness Rating of A and Sponsorship Rating of B.

There are 170.3 million shares outstanding (S criteria). CTLT completed new Public Offerings in Jun '20, Feb '20, Jul '18, and Sep '17. Completed Secondary Offerings in Jun and Sep '16, and Mar and Jun '15. Completed its $21 IPO on 7/31/14.

Recent Violation of 50-Day Moving Average Triggered Sell Signal - Thursday, November 11, 2021

Found Support Near Prior High While Consolidating - Friday, October 8, 2021

Strong Gain Triggered Technical Buy Signal - Wednesday, August 25, 2021